Geron Corporation
Tracked across 2 events · 13 articles · First seen Mar 13, 2025 · Last active Jul 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Geron Corporation announced positive real-world evidence study results for its drug RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS), which supports its continued use and potential for expanded treatment options.
May 12, 2026 · 6 articles
Business
Impact: Geron granted stock options to new employees as inducements, a standard practice for attracting talent. The grants are non-dilutive in the short term and align with Nasdaq rules.
Jul 14, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Geron Corporation live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard